PolyOne Announces Strong Fourth Quarter and Full Year 2013 Results GOBIE® H2O Boosts Competitive Advantage for Filtered Water Bottle with PolyOne PolyOne To Hold Fourth Quarter 2013 Conference Call

Versaflex™ HC and Versaflex™ HC BIO Thermoplastic Elastomers TPEs for Biopharmaceutical Tubing (BT) The Versaflex™ HC and Versaflex™ HC BIO BT series is formulated specifically to handle the complexities of biopharma tubing. KEY CHARACTERISTICS • Meets critical need for thermal weldability and kink resistance • Minimizes extractables during processing • Provides excellent tensile strength • Complies with USP VI and ISO 10993-4, -5, -11 certifications • Suitable for gamma and autoclave sterilization methods • Bio-based grade option formulated with nearly 40% Gen 1 biomass content PRODUCT OVERVIEW 1.844.4AVIENT www.avient.com Copyright © 2023, Avient Corporation.

July 1, 2020 PolyOne PolyOne

About PolyOne To access PolyOne’s news library online, please go to www.polyone.com/news Media contact Matt Defosse Marketing Communications Manager, Europe PolyOne Corporation +49 6407-907-0386 matt.defosse@avient.com

PolyOne Corporation Investor Day 2012 PolyOne Investor Presentation Sidoti & Company Eighteenth Annual Emerging Growth Institutional Investor Forum March 18, 2014 • In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. PolyOne Investor Presentation��Sidoti & Company �Eighteenth Annual Emerging Growth �Institutional Investor Forum�March 18, 2014� Forward – Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation Strategy and Execution Drive Results PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Proof of Performance & 2015 Goals Bridge To $2.50 Adjusted EPS By 2015 Innovation Drives Earnings Growth Unique and Innovative Solutions that Help Customers Win Debt Maturities & Pension Funding – 12/31/13 Free Cash Flow and Strong Balance Sheet Fund Investment Why Invest In PolyOne? Appendix At a Glance�Global Specialty Engineered Materials At a Glance�Global Color, Additives, and Inks At a Glance�Designed Structures and Solutions At a Glance�Performance Products and Solutions At a Glance�Distribution Plastics: Key to Future Sustainable Development Establish Lean Six Sigma As Way of Life Application Examples Slide Number 24 2012 Range Rover Evoque Interior Slide Number 26 Slide Number 27 Metal Replacement Solutions High-Barrier Packaging Containers Aerospace Applications Sidoti Reconciliation of Non-GAAP.pdf Section 1

Gaskets and stoppers can benefit from our Versaflex™ HC TPEs, which feature no coring and high resealability for dynamic and static seals and stoppers. Our Versaflex™ HC TPEs deliver exceptional extrusion rates in high clarity grades without plasticizers, and are also available in formulations that withstand high service temperatures. Versaflex™ CL E Series materials feature high clarity before and after autoclaving, with high flexibility and low extractables.

Microsoft Word - PolyOne_English_Thai_Terms and Conditions.docx TERMS AND CONDITIONS These Terms and Conditions apply to the sale of Products by PolyOne Corporation and its subsidiaries. ขอ้กาํหนดและเงื�อนไข ขอ้กาํหนดและเงื� อนไขเหลา่นี� ใชบ้งัคบักบัการขาย สินคา้ของโพลีวนั คอรป์อเรชั�น และบรษิัทในเครอื 1. These Terms and Conditions apply to all sales by PolyOne Corporation and its affiliated companies.

PolyOne Corporation Investor Day 2012 CFA Society Cleveland Midwest Investment Conference 2013 PolyOne Investor Presentation November 19, 2013 • In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Use of Non-GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Page 4 All time high of $32.32 October 21st, 2013 • 16 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 56% versus 22% growth in the S&P • Six fold increase in market cap: $0.5b $3.0b Strategy and Execution Drive Results PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 5 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 63% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 YTD 2013 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $153M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 6 2006 YTD 2013 2015 Where we were Where we are Organic Consolidated Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.8% 12.8% 12 – 16% Global Specialty Engineered Materials 1.1% 10.8% 8.9% 12 – 16% Designed Structures & Solutions — — 5.0% 8 – 10% Performance Products & Solutions 5.5% 8.0% 8.2% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 63% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 28% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 7 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 44.0% 2006 Q3 2013 $20.3 $46.6 2006 TTM Q3'13 14.3% 31.0% 2006 Q3 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 8 We are Experts in Polymer Science and Formulation  Polymer Science  Formulation  Chemistry  Processing Inputs  Base Resins  Additives  Modifiers  Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services  Marketplace Demands  Performance Requirements  Value Drivers Page 9 Positioned for Strong Growth 2015 Target Rev: $5B Adj. Average Debt Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Average PolyOne Debt $ 705.2 $ 706.9 $ 1,055.5 $ 1,031.2 $ 987.7 $ 897.3 Average Equity Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Average PolyOne shareholders’ equity $ 629.3 $ 629.1 $ 871.8 $ 993.9 $ 996.6 $ 824.1 Reconciliation to Condensed Consolidated Balance Sheets YTD 2013 Short-term debt and current portion of long-term debt $ 9.9 Long-term debt 977.8 Less cash and cash equivalents (322.8) Net debt $ 664.9 Adjusted EBITDA Q4 2012 Q1 2013 Q2 2013 Q3 2013 Total PolyOne Income before income taxes $ (1.1) $ 15.7 $ 62.9 $ 38.8 $ 116.3 PolyOne Interest expense, net 13.7 15.6 16.6 16.0 61.9 PolyOne Depreciation and amortization 15.5 19.0 25.8 30.3 90.6 PolyOne Special items in EBITDA 26.5 27.7 (5.2) 11.2 60.2 PolyOne Adjusted EBITDA 54.6 78.0 100.1 96.3 329.0 Pro forma Spartech EBITDA 14.7 11.2 - - 25.9 Pro forma EBITDA $ 69.3 $ 89.2 $ 100.1 $ 96.3 $ 354.9 CFA Society Cleveland �Midwest Investment Conference 2013��PolyOne Investor Presentation �November 19, 2013� Forward – Looking Statements Use of Non-GAAP Measures Strategy and Execution Drive Results PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Proof of Performance & 2015 Goals Innovation Drives Earnings Growth We are Experts in Polymer Science and Formulation Positioned for Strong Growth Q3 2013 Financial Highlights Debt Maturities & Liquidity Summary – 9/30/13 Use of Cash Why Invest In PolyOne?

Like other Mevopur products, they are formulated with raw materials tested to ISO 10993-1 and USP , European Pharmacopeia 3.1.3 and 3.1.5, USP and ICH Q3D.   Another bio-based solution that can help healthcare manufacturers decrease the carbon footprint of their products is the recently launched Versaflex™ HC BIO thermoplastic elastomer (TPE). Certified for USP Class VI and ISO 10993, the new Versaflex HC BIO BT218 grade is commercially available globally.

PINK VR-1 VERSOLLAN(TM) OM 1255NX-1 NATURAL Shipment Notification - under "Material Header" MSDS - labeled as the "Product Number" (in Section 1)